Merus B.v.
Clinical trials sponsored by Merus B.v., explained in plain language.
A clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug duo aims to shrink lung tumors in First-Line trial
Disease control TerminatedThis phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many pat…
Phase: PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC